The Source Blog
Recent Action in Pharmaceuticals
Introduced: 2025 Status: In Process
This bill establishes prescription drug pricing disclosure requirements and measures to reduce prescription drug costs. It requires pharmacy benefits managers (PBMs) to disclose information about prescription drug and biological product pricing and generic substitutions to […]
A 3621 – New Jersey
Introduced: 2025 Status: In Process
This bill prohibits manufacturers and wholesale distributors of prescription drugs and biological products from engaging in price gouging, defined as an excessive and unjustified increase in the price of certain essential off-patent or generic drugs […]
HB 1119 – Mississippi
Introduced: 2025 Status:
This bill renames the “Pharmacy Benefit Prompt Pay Act” to the “Representative Andy Stepp Pharmacy Benefit Prompt Pay Act” and introduces comprehensive reforms to regulate pharmacy benefit managers (PBMs) in Mississippi. The bill defines key […]
HB 1124 – Mississippi
Introduced: 2025 Status:
This bill requires pharmacy benefit managers (PBMs) to disclose detailed financial information and contract details, enhancing transparency in prescription drug pricing. Specifically, PBMs must disclose 100% of all rebates and payments received from pharmaceutical manufacturers […]
S 479 – North Carolina
Introduced: 2025 Status: In Process
This bill, known as the SCRIPT Act (Supporting Community Retail Pharmacies and Improving Transparency), is a comprehensive legislative effort to regulate pharmacy benefits managers (PBMs), improve pharmacy services, and enhance prescription drug transparency. The bill […]
SB 12 – Kentucky
Introduced: 2025 Status: In Process
This bill amends Kentucky law to establish new requirements for prescription drug cost-sharing and rebates in health insurance plans. The bill defines key terms like “rebate” and “cost sharing” and mandates that at least 85% […]
SB 357 – Maryland
Introduced: 2025 Status: In Process
This bill expands the authority and membership of Maryland’s Prescription Drug Affordability Board (the Board) and its Stakeholder Council to help control prescription drug costs. The bill creates a more diverse 26-member Stakeholder Council, with […]
Previous | Next | See all Legislation Records
District Court: District of Columbia Status: Pending
A complaint filed by Merck, a multinational pharmaceutical company, alleges that the drug price negotiation process detailed in the Inflation Reduction Act (IRA) violates the […]
FTC v. Amgen Inc. & Horizon Therapeutics Plc. – Federal
District Court: Northern District of Illinois, Eastern Division Status: Pending
The FTC filed a lawsuit requesting a temporary restraining order and preliminary injunction to block Amgen Inc. from acquiring Horizon Therapeutics. Amgen agreed to purchase […]
PhRMA v. Stolfi – Oregon
District Court: District Court of Oregon Status: Decided
PhRMA is challenging Oregon’s drug price transparency laws HB 4005, 2018 (Disclosure Law) and HB 2658, 2019 (Advance Notification Law) alleging that the laws are […]
Pharmaceutical Care Management Association (PCMA) v. Mulready – Oklahoma
District Court: District Court of Western District of Oklahoma Status: Decided
The 2019 Oklahoma law, Patient’s Right to Pharmacy Choice Act, targets PBM conflict of interest by prohibiting higher reimbursement rates for PBM-owned pharmacies and bans […]
State of Ohio v. OptumRx – Ohio
District Court: Ohio Court of Common Pleas (Franklin County) Status: Pending
On March 15, 2019, Ohio’s attorney general Dave Yost sued OptumRx in Ohio state court, claiming that between 2015 and 2018, the PBM failed to pass […]
Pharm. Care Mgmt. Ass’n v. Gerhart – Iowa
District Court: Southern District of Iowa Status: Decided
Trade association representing pharmacy benefits managers (PBM) brought action against State of Iowa, seeking declaration that statute that regulated how PBMs established generic drug pricing […]
Pharm. Care Mgmt. Ass’n v. Tufte – North Dakota
District Court: District of North Dakota Status: Pending
Trade association representing pharmacy benefit managers (PBMs) brought action against North Dakota state officials in their official capacities, alleging that Employee Retirement Income Security Act […]
Next | See all Litigation Records
News & Opinions
Articles & Reports
Health Affairs June 3, 2025
Health Affairs May 27, 2025
Journal of Healthcare Provision and Public Health May 14, 2025
Trends in Pharmaceuticals
State Pharmaceutical Legislation
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
2019 Drug Pricing Transparency Legislation
Pharmaceutical price transparency legislation requires disclosures from drug manufacturers and insurers to help lawmakers and the public better understand how drugs are priced and how those prices affect insurance premiums. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Pharmaceutical Rate-Setting Legislation
Rate setting legislation either establishes the price of a prescription drug or sets the maximum amount a payer can pay for a drug. Click on highlighted states to see rate-setting legislation considered or enacted in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Drug Importation Legislation
Click on highlighted states to see drug importation legislation considered or enacted in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Drug Price Gouging Prohibition Legislation
Price gouging prohibitions typically empower the state Attorney General to act if the price of a drug is raised above a threshold. Click on highlighted states to see legislation considered in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Pharmacy Benefit Manager Regulation Legislation
Legislation to regulate Pharmacy Benefit Managers (PBMs) typically include provisions that 1) require PBMs to register with the state, 2) mandate disclosures by PBMs, or 3) prevent PBMs from incentivizing the use of mail-order pharmacies. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered